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Abstract
Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of
patients with haematological malignancies (HM) and Escherichia coli represent one of the
most frequent cause of such infections. In this study, we aimed to describe risk factors for
resistance to third generation cephalosporins and prognostic factors, including the impact of
third generation cephalosporins resistance, in patients with HM and BSIs caused by E. coli.
Three hundred forty-two cases of E. coli BSIs were collected during the study period (from
January 2016 to December 2017). The percentage of resistance to third generation cepha-
losporins was 25.7%. In multivariate analysis, the variables recent endoscopic procedures,
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culture-positive surveillance rectal swabs for multidrug-resistant bacteria, antibiotic prophy-
laxis with fluoroquinolones, and prolonged neutropenia were independently associated with
bloodstream infections caused by a third generation cephalosporins resistant E. coli. The
overall 30-day mortality rate was 7.1%. Cox regression revealed that significant predictors
of mortality were acute hepatic failure, septic shock, male sex, refractory/relapsed HM, and
third generation cephalosporins resistance by E. coli isolate. In conclusion, resistance to
third generation cephalosporins adversely affected the outcomes of bloodstream infections
caused by E. coli in our cohort of HM patients. We also found a significant correlation
between prophylaxis with fluoroquinolones and resistance to third generation cephalospo-
rins by E. coli isolates.
Introduction
Although several advances have been made in clinical management of patients with haemato-
logical malignancies (HM), bloodstream infections (BSIs) remain life-threatening complica-
tions in the clinical course of these patients, with reported crude mortality rate up to 40% [1–
6]. A clear shift of bacterial species causing BSI in HM patients has been reported during the
last decade from Gram-positives to Gram-negatives, and among the latter, Enterobacteriaceae,
and in particular Escherichia coli (EC), represent the most frequent involved bacterial species
[2,6]. Moreover, a worrisome increase in antimicrobial-resistance among Enterobacteriaceae
has been described in HM patients due mainly to production of extended-spectrum-b-lacta-
mases (ESBLs) and/or carbapenemases by bacterial isolates, which often show a multidrug-
resistant (MDR) phenotype with limited treatment options [1–3,6,7]. Resistance to third gen-
eration cephalosporins (3GC) by Enterobacteriaceae, which represents the major mechanism
of antimicrobial resistance among EC isolates, has been reported as independently associated
with a poor outcome in HM patients with severe infections caused by EC [4,8,9].
The aim of the present large multicenter study was to identify risk factors for 3GC resis-
tance by EC isolates and prognostic factors, including the impact of 3GC resistance, in HM
patients with BSIs caused by EC. The impact of empirical and definitive therapy with carbape-
nems vs. piperacillin/tazobactam on 30-day mortality was also evaluated.
Methods
We conducted a prospective cohort study in 15 Italian haematological wards of tertiary care
centers or university hospitals participating to Haematologic Malignancies Associated Blood-
stream Infections Surveillance (HEMABIS) registry–Sorveglianza Epidemiologica Infezioni
Fungine in Emopatie Maligne (SEIFEM) group throughout Italy from January 2016 and
December 2017. In participating centers where antimicrobial prophylaxis was administered to
high-risk patients, it was performed according to Gruppo Italiano Malattie Ematologiche del-
l’Adulto (GIMEMA) criteria [10].
All HM patients admitted to participating centers were screened at admission for coloniza-
tion by multidrug-resistant (MDR) bacterial isolates with a rectal swab; each hospital con-
ducted rectal swab screening according to its own protocols, as described elsewhere [11].
All episodes of BSI caused by EC (EC BSI) occurring in hospitalized HM adult patients
were included. Data collected from the hospital charts and the laboratory database included
patient demographics, disease and disease stage at time of EC BSI, type of hematopoietic stem
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cell transplantation (HSCT) (autologous or allogeneic), and outcome of infection; for each
bacterial isolate, the antimicrobial susceptibility was recovered and analyzed. All information
was entered in case report forms and then recorded in a specific database. Recurrent as well as
polymicrobial infections were excluded.
Patients with 3GC resistant (3GCR) EC BSI were compared with those with 3GC suscepti-
ble (3GCS) EC BSI in order to identify risk factors for infection by 3GCR EC isolates.
The outcome measured in our EC BSI patients cohort was death within 30 days of the first
positive blood culture. Survivor and non-survivor subgroups were compared in order to iden-
tify predictors of mortality.
Upon approval of ethic committee of the study coordinating center (Fondazione Policlinico
Universitario Agostino Gemelli IRCCS–Università Cattolica del Sacro Cuore), also the ethics
committee of each participating site approved the use of the HeMABIS-SEIFEM registry and
written informed consent was obtained by each patient.
Definitions
The following terms were defined prior to data analysis:
EC BSI was defined as an infection manifested by the presence in at least 1 blood culture
that grew an EC strain.
Neutropenia was defined as an absolute neutrophil count (ANC) <500 neutrophils/μL at
the onset of BSI; neutropenia was considered prolonged if the duration was�10 days and
severe if ANC was <100 neutrophils/μL.
EC BSI was considered hospital-acquired if the index culture had been collected >48 hours
after admission and signs and symptoms of infection were absent at admission. If cultures had
been collected�48 hours after the admission date, the isolate was classified as healthcare-asso-
ciated or community-acquired [12].
The empirical therapy was classified as inadequate if antibiogram demonstrated resistance
of EC isolate to the administered antimicrobial(s).
Septic shock was defined according to Surviving Sepsis Campaign criteria [13].
Statistical analysis
Continuous variables were compared by Student’s t test for normally distributed variables and
the Mann-Whitney U test for non-normally distributed variables. Categorical variables were
evaluated using the χ2 or two-tailed Fisher’s exact test. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated to evaluate the strength of any association that emerged. Values
are expressed as means ± standard deviation (SD) (continuous variables), or as percentages of
the group from which they were derived (categorical variables). Two-tailed tests were used to
determine statistical significance; a P value of<0.05 was considered significant. Multivariate
analysis was used to identify independent risk factors for 3GCR EC BSI and Cox regression
analysis was conducted to identify independent risk factors for 30-day mortality. Variables
emerging from univariate analyses for 3GCR EC BSI and 30-day mortality with P values of
<0.1 were included in a backward stepwise manner in the multivariate and the Cox regression
models, respectively,. The Kaplan-Meier method was used for survival analysis. All statistical
analyses were performed using the Intercooled Stata program, version 11, for Windows (Stata
Corporation, College Station, Texas, USA).
Results
A total of 342 cases of EC BSI were collected during the study period. The rate of resistance to
3GC among EC isolates was 25.7% (88/342). Compared to 3GCS EC isolates, 3GCR EC isolates
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were more likely to be resistant to fluoroquinolones (FQ) (80/88, 90.9%, vs. 161/254, 63.4%;
P<0.001), piperacillin/tazobactam (25/88, 28.4%, vs. 34/254, 13.4%; P<0.001), amikacin (23/
88, 26.1%, vs. 16/254, 6.3%; P<0.001), and gentamicin (33/88, 37.5%, vs. 35/254, 13.8%;
P<0.001) (Fig 1). Only two EC isolates (0.6%), both resistant to 3GC, displayed resistance to
carbapenems.
Risk factors for third-generation resistance in patients with EC BSI
In Table 1 clinical and epidemiological characteristics of EC BSI cohort patients according to
3GC resistance are shown. Compared to patients with 3GCS EC BSI, those with 3GCR EC BSI
more likely had undergone endoscopic procedures (9/88, 10.2%, vs. 7/254, 2.8%; P = 0.004)
and/or parenteral nutrition (25/88, 28.4%, vs. 44/254, 17.3%; P = 0.02) and/or allogeneic-
matched unrelated HSCT (9/88, 10.2%, vs. 9/254, 3.5%; P = 0.01), had prolonged neutropenia
(53/88, 60.2%, vs. 118/254, 46.5%; P = 0.02), had previous MDR Gram-negative bacteria cul-
ture-positive surveillance rectal swabs (32/88, 36.4%, vs. 42/254, 16.5%; P<0.001), and received
antibiotic prophylaxis with FQ (56/88, 63.6%, vs. 119/254, 46.9%; P = 0.006). Patients suffering
from multiple myeloma had more frequently a 3GCS EC BSI (26/254, 10.2% vs. 3/88, 3.4%;
P = 0.05). No other variable was associated with 3GCS EC BSI, with particular reference to
demographic characteristics, type of HM or primary site of BSI.
In multivariate analysis, the variables recent endoscopic procedures (OR 3.68, 95% CI 1.23–
11.01; P = 0.02), MDR bacteria culture-positive surveillance rectal swabs (OR 2.81, 95% CI
1.59–4.95; P<0.001), antibiotic prophylaxis with FQ (OR 1.94, 95% CI 1.16–3.28; P = 0.01),
and prolonged neutropenia (OR 1.82, 95% CI 1.08–3.06; P = 0.02) were found to be indepen-
dently associated with BSI caused by a 3GCR EC isolate (Table 2).
Risk factors for 30-day mortality in patients with EC BSI
The 24 (7.1%) patients who died within 30 days of EC BSI onset included 12 of the 88 (13.6%)
whose EC isolate was resistant to 3GC and 12/254 (4.7%) who had a BSI caused by a 3GCS EC
(P = 0.004). The 30-day survival distributions were also significantly different in HM patients
with 3GCR EC BSI vs. 3GCS EC BSI (P = 0.007)(Fig 2).
Fig 1. Percentages of resistance to the more commonly used antibiotics for treatment of Escherichia coli infections
according to resistance to 3rd generation cephalosporins.
https://doi.org/10.1371/journal.pone.0224465.g001
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Table 1. Clinical and demographic characteristics of patients with hematological malignancies and BSI caused by Escherichia coli according to resistance of isolate
to third-generation cephalosporins.






Male sex 49 (55.7) 149 (58.7) 0.62
Age > 65 years 18 (20.5) 61 (24.0) 0.49
Patient’s characteristics
Indwelling CVC 81 (92.0) 223 (87.8) 0.27
Indwelling urinary catheter 13 (14.8) 40 (15.7) 0.82
Endoscopic procedures§ 9 (10.2) 7 (2.8) 0.004
Parenteral nutrition§ 25 (28.4) 44 (17.3) 0.02
Diabetes mellitus 11 (12.5) 32 (12.6) 0.98
Chronic hepatic failure 1 (1.1) 16 (6.3) 0.30
Chronic renal failure 1 (1.1) 13 (5.1) 0.10
PMN < 500/mmc 80 (90.9) 227 (89.3) 0.68
PMN < 100/mmc 77 (87.5) 206 (81.1) 0.17
PMN < 500/mmc for at least 10 days 54 (61.4) 118 (46.5) 0.02
Corticosteroid treatment§ 33 (37.5) 119 (46.8) 0.12
Chemotherapy§ 69 (78.4) 210 (82.7) 0.37
Radiotherapy§ 3 (3.4) 17 (6.7) 0.25
Therapy with monoclonal antibodies§ 14 (15.9) 41 (16.1) 0.95
Previous antibiotic therapy^ 28 (31.8) 52 (20.5) 0.03
Hematological malignancy
Acute myeloid leukemia/myelodysplastic syndrome 51 (58.0) 132 (52.0) 0.33
Chronic myeloid leukemia 2 (2.3) 2 (0.8) 0.26
Acute lymphoblastic leukemia 8 (9.1) 24 (9.4) 0.92
Lymphomas/chronic lymphoid leukemia 24 (27.3) 70 (27.6) 0.95
Multiple Myeloma 3 (3.4) 26 (10.2) 0.05
Stage of Hematological Disease
Newly diagnosed / Relapsed after 1st remission 21 (23.7) 50 (19.7) 0.40
Complete remission 17 (19.3) 49 (19.3) 0.99
Refractory / Relapsed after 2 or more remissions 17 (19.3) 70 (27.6) 0.12
Hematopoietic stem cell transplantation 33 (37.5) 85 (33.5) 0.49
Autologous 16 (18.2) 50 (19.7) 0.75
Allogeneic-Matched Related 3 (3.4) 11 (4.3) 0.70
Allogeneic-Matched Unrelated 9 (10.2) 9 (3.5) 0.01
Allogeneic-Mismatched 5 (5.7) 15 (5.9) 0.94
Characteristics of BBSI
Hospital acquired 72 (81.8) 216 (85.1) 0.47
Healthcare-associated 16 (18.2) 38 (15.0) 0.47
Primary site of BSI
Urinary tract 3 (3.4) 13 (5.1) 0.51
Respiratory tract 2 (2.3) 5 (2.0) 0.86
CVC 25 (28.4) 61 (24.0) 0.41
Others 3 (3.4) 12 (4.7) 0.60
Unidentified 58 (65.9) 167 (65.7) 0.97
MDR bacteria culture-positive surveillance rectal swabs§ 32 (36.4) 42 (16.5) <0.001
Antibiotic fluoroquinolones prophylaxis 56 (63.6) 119 (46.9) 0.006
Antifungal prophylaxis 49 (55.7) 137 (53.9) 0.77
(Continued)
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In univariate analysis (described in Table 3), variables associated to 30-day mortality were:
septic shock (14/24, 58.3%, vs. 46/318, 14.5%; P<0.001), altered state of consciousness (11/24,
45.8%, vs. 23/318, 7.2%; P<0.001), acute renal (10/24, 41.7%, vs. 18/318, 5.6%; P<0.001) and/
or respiratory (8/24, 33.3%, vs. 11/318, 3.4%; P<0.001) and/or hepatic failure (5/24, 20.8%, vs.
1/318, 0.3%; P<0.001), and 3GC resistance by EC isolate(12/24, 50%, vs. 76/318, 23.9%;
P = 0.004). On the other hand, autologous HSCT (1/24, 4.2%, vs. 65/318, 20.4%; P = 0.05) and/
or complete remission stage of HM disease (0/24 vs. 66/318, 20.8%; P = 0.01) were significantly
associated with survival. No other variable was associate to 30-day mortality, in particular with
regard to patient’s characteristics (including neutropenia, regardless of severity and duration),
type of HM, and inadequate initial antimicrobial therapy.
In Cox regression, significant predictors of mortality were acute hepatic failure (HR 9.90,
95% CI 3.08–31.73; P<0.001), septic shock (HR 8.56, 95% CI 3.33–21.95; P<0.001), male sex
(HR 6.46, 95% CI 2.19–19.01; P = 0.001), refractory/relapsed HM (HR 3.25, 95% CI 1.35–7.83;
P = 0.008), and 3GC resistance by EC isolate (HR 3.18, 95% CI 1.36–7.43; P = 0.007) (Table 4).
Empirical and definitive antibiotic treatment in patients with EC BSI
Empirical antimicrobial treatment was started within a few hours after the index blood culture
was drawn in all 342 cases. In vitro susceptibility testing results showed that empirical therapy
was inadequate in 51/342 (14.9%) cases. The rate of initial inadequate antibiotic therapy was
significantly more frequent in patients with 3GCR EC BSI compared to those with 3GCS EC
BSI (25/88, 28.4% vs. 26/254, 10.2%; P<0.001).
Among the 88 patients suffering from 3GCR EC BSI, the 30-day mortality rate did not dif-
fer significantly between those initially treated with an antibiotic regimen containing piperacil-
lin/tazobactam compared to other regimens (7/42, 16.7% vs. 5/46, 10.9%; P = 0.42), as well as
there was not any significant difference in mortality between patients who had empirically
received an antibiotic regimen including a carbapenem compared those treated with other reg-
imens (3/31, 9.7% vs 9/57, 15.8%; P = 0.42). Including only patients who had received
Table 1. (Continued)





Time at risk (days, mean ± SD) 15 ± 14 13 ± 9 0.22
Inadequate initial antimicrobial therapy 25 (28.4) 26 (10.2) <0.001
21-day mortality 12 (13.6) 12 (4.7) 0.004
Abbreviations: CVC, central venous catheter; PICC, peripherally inserted central catheter; PMN, polymorphonuclear leukocytes; 3GCR, 3rd generation cephalosporins
resistant; 3GCS, 3rd generation cephalosporins susceptible.
§During the last 30 days
^ During the last 90 days
https://doi.org/10.1371/journal.pone.0224465.t001
Table 2. Multivariate analysis of risk factors for 3rd generation cephaloporins in patients with hematological
malignancies and BSI caused by Escherichia coli.
Variables OR (95% IC) P values
Recent endoscopic procedures 3.68 (1.23–11.04) 0.02
MDR bacteria culture-positive surveillance rectal swabs 2.81 (1.59–4.95) <0.001
Antibiotic prophylaxis with fluoroquinolones 1.95 (1.16–3.28) 0.01
PMN < 500/mmc for at least 10 days 1.82 (1.08–3.06) 0.02
https://doi.org/10.1371/journal.pone.0224465.t002
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empirical regimens based on piperacillin/tazobactam or carbapenems (73/88), there was not
any significant difference between those treated with carbapenems compared to those treated
with piperacillin/tazobactam (3/31, 9.7% vs. 7/42, 16.7%; P = 0.39).
Similarly, among the 84/88 patients with carbapenem-susceptible EC BSI and who had
been treated with definitive regimens based on carbapenems or piperacillin/tazobactam, there
were no significant differences in the 30-day mortality rates between those treated with carba-
penems vs. those treated with piperacillin/tazobactam (9/58, 15.5% vs. 2/26, 7.7%; P = 0.32).
Discussion
In the present study conducted in 15 Italian Haematological Units we found that the rate of
resistance to 3GC among EC isolates was 25.7% (88/342). Compared to previous epidemiologi-
cal data from the HeMABIS-SEIFEM registry collected from 2009 to 2012, the percentage of
resistance to 3GC among EC isolates has not increased, rather it is slightly reduced (25.7% vs.
30%) [2]. Similarly, resistance to 3GC among EC isolates was slightly lower than that reported
in Italian general population during the same period (2016 to 2017) by Antimicrobial Resis-
tance Surveillance in Europe (EARSS) (25.7% vs. 29.6%) [14] and it was substantially in line
with reports conducted in HM or cancer patients in other countries [9,15–17]. These data
indicate that, in contrast to other MDR Gram-negative bacteria (e.g. carbapenem-resistant
Klebsiella pneumoniae) for which a worrisome increasing trend in frequency has been recently
highlighted in the HeMABIS-SEIFEM registry previous survey in HM patients [3], the rate of
resistance to 3GC among EC isolates remained stable during the last years. Interestingly, the
result was considerably decreased compared to what reported in studies published worldwide
in cancer patients from 2007 to 2013 (mean 53.3% rate of resistance to ceftazidime) [1].
We investigated risk factors for 3GCR EC BSI and found that recent endoscopic proce-
dures, previous culture-positive surveillance rectal swabs, prolonged neutropenia, and antibi-
otic prophylaxis with FQ were independently associated with 3GCR EC BSI. While the first
three risk factors have been widely described as related with BSI due to ESBL-producing or
MDR Enterobacteriaceae both in general population and in onco-haematological patients
Fig 2. Kaplan-Meier survival estimates among patients with bloodstream infections caused by 3rd generation
cephalosporins resistant and 3rd generation cephalosporins susceptible Escherichia coli.
https://doi.org/10.1371/journal.pone.0224465.g002
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[11,18–20], the role of FQ prophylaxis in increased rate of infections caused by MDR Gram-
negative bacteria remains actually a topic widely debated, also considering the burden of anti-
microbial resistance, particularly in Enterobacteriaceae, worldwide throughout the last decades
[1,21]. In line with our results, previous exposure to antimicrobials, and in particular FQ, has
been largely demonstrated as one of the most important risk factors for colonization and/or





OR (95% IC) P values
Demographic information
Male sex 19 (79.2) 179 (56.3) 2.95 (1.03–10.33) 0.02
Age > 65 years 8 (33.3) 71 (22.3) 1.73 (0.61–4.51) 0.21
Patient’s characteristics
Diabetes mellitus 5 (20.8) 38 (11.9) 1.93 (0.53–5.78) 0.20
Chronic hepatic failure 3 (12.5) 16 (5.0) 2.69 (0.46–10.522) 0.12
Chronic renal failure 2 (8.3) 12 (3.8) 2.31 (0.23–11.42) 0.27
PMN < 500/mmc 20 (83.3) 287 (90.3) 0.54 (0.16–2.31) 0.28
PMN < 100/mmc 17 (70.8) 266 (83.6) 0.47 (0.17–1.42) 0.10
PMN < 500/mmc for at least 10 days 9 (37.5) 163 (51.3) 0.57 (0.21–1.43) 0.19
Corticosteroid treatment 11 (45.8) 141 (44.3) 1.06 (0.41–2.65) 0.88
Chemotherapy 16 (66.7) 263 (82.7) 0.41 (0.15–1.19) 0.43
Radiotherapy 1 (4.2) 19 (6.0) 0.68 (0.01–4.71) 0.71
Therapy with monoclonal antibodies 5 (20.8) 50 (15.7) 1.41 (0.39–4.14) 0.51
Hematological malignancy
Acute myeloid leukemia/ myelodysplastic syndrome 11 (45.8) 172 (54.1) 0.71 (0.28–1.79) 0.43
Chronic myeloid leukemia 0 4 (1.3) - 0.58
Acute lymphoblastic leukemia 3 (12.5) 29 (9.1) 1.42 (0.25–5.20) 0.58
Lymphomas/chronic lymphoid leukemia 8 (33.3) 86 (27.1) 1.34 (0.48–3.48) 0.50
Multiple Myeloma 2 (8.3) 27 (8.5) 0.97 (0.10–4.35) 0.97
Stage of Hematological Disease
Newly diagnosed / Relapsed after 1st remission 7 (29.2) 64 (20.1) 1.63 (0.54–4.35) 0.29
Complete remission 0 66 (20.8) - 0.01
Refractory / Relapsed after 2 or more remissions 10 (41.7) 77 (24.2) 2.23 (0.84–5.64) 0.06
Hematopoietic stem cell transplantation 7 (29.2) 111 (34.9) 0.76 (0.26–2.02) 0.56
Autologous 1 (4.2) 65 (20.4) 0.16 (0.01–1.08) 0.05
Allogeneic-Matched Related 2 (8.3) 12 (3.8) 2.31 (0.23–11.42) 0.27
Allogeneic-Matched Unrelated 1 (4.2) 17 (5.3) 0.76 (0.01–5.37) 0.80
Allogeneic-Mismatched 3 (12.5) 17 (5.3) 2.52 (0.43–9.78) 0.15
Clinical characteristics of BSI
Septic shock 14 (58.3) 46 (14.5) 8.27 (3.17–21.99) <0.001
Altered state of consciousness 11 (45.8) 23 (7.2) 10.85 (3.88–29.34) <0.001
Acute renal failure 10 (41.7) 18 (5.7) 11.90 (4.06–33.26) <0.001
Acute respiratory failure 8 (33.3) 11 (3.5) 13.95 (4.18–43.85) <0.001
Acute hepatic failure 5 (20.8) 1 (0.3) 83.42 (8.39–3955.44) <0.001
Granulocyte transfusion 1 (4.2) 11 (3.5) 1.21 (0.02–9.05) 0.58
Antibiotic fluoroquinolones prophylaxis 12 (50.0) 163 (51.3) 0.95 (0.37–2.39) 0.90
Inadequate initial antimicrobial therapy 2 (8.3) 49 (15.4) 0.49 (0.05–2.14) 0.34
3rd generation cephalosporins resistance by EC isolate 12 (50.0) 76 (23.9) 3.18 (1.24–8.04) 0.004
Abbreviations: PMN, polymorphonuclear leukocytes.
https://doi.org/10.1371/journal.pone.0224465.t003
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infection by ESBL- or carbapenemase-producing Enterobacteriaceae both in general popula-
tion and HM patients [1,4,9,16–18,22]. To this regard, European Conference on Infections in
Leukemia (ECIL) has recently conducted a meta-analysis in order to evaluate the role of FQ
prophylaxis in onco-haematological patients; it concluded that FQ prophylaxis did not have
effect on mortality while was associated with lower rate of BSI and episodes of febrile neutro-
penia without a clear effect of the background rate of FQ resistance on the efficacy of FQ pro-
phylaxis [23]. Despite FQ prophylaxis independently predicted 3GCR, no correlation was
found between FQ prophylaxis and 30-day mortality in our cohort of HM patients, and this
could at least be partially due to the specific focus of the present study on EC BSIs.
The overall 30-day mortality rate in our cohort was 7.0% (24/342); compared to previous
studies on EC BSI in HM or cancer patients, it was considerably lower [4,7–9].
By cox regression analysis, the most important risk factors for mortality in our cohort were
acute respiratory failure and septic shock at EC BSI onset; not surprisingly, similar variables
(e.g. admission to Intensive Care Unit, etc.), indicating clinical severity of BSI, had been
reported to be associated with mortality in several previous studies conducted on HM or can-
cer patients with EC BSI [4,7,9]. Male sex and refractory/relapsed HM also were found to be
independently associated with mortality, as previously reported in general or HM populations
suffering from bacterial BSIs [24,25]. Finally, the resistance to 3GC by EC isolate emerged as
variable independently associated with 30-day mortality in our cohort. In line with our data,
antibiotic-resistance by Gram-negative bacteria has been reported to be strongly associated
with mortality in several previous studies conducted in HM patients with BSI [1,26]. In partic-
ular, ESBL production (i.e. resistance to 3GC) has been associated with mortality in HM or
cancer patients with EC BSI [4,8,9]. The relationship between infection with antibiotic resis-
tant bacteria and mortality is not completely clear and it has been often related to a delay in
the initiation of an appropriate antibiotic therapy [1,8]. Of note, in our study, inadequacy of
empirical antibiotic therapy, although significantly more frequent in patients with 3GCR EC
BSI, was not associated with a poorer outcome, in line with other studies [7,9,15,16].
A recent randomized clinical trial investigating the effect of definitive antimicrobial therapy
with piperacillin-tazobactam vs. meropenem on 30-day mortality in patients with BSIs caused
by ceftriaxone-resistant EC or Klebsiella pneumoniae isolates, demonstrated that definitive
treatment with piperacillin-tazobactam failed to be non-inferior to meropenem, thus not sup-
porting the use of piperacillin-tazobactam in this setting [27]. In our prospective observational
cohort of 88 3GCR EC BSI patients, we did not find any significant difference in 30-day mor-
tality between those treated both empirically or definitively with regimens based on piperacil-
lin-tazobactam vs. meropenem. These findings are in line with those of Gudiol et al. who have
recently conducted a study comparing the efficacy of β-Lactam/β-lactamase inhibitors
(BLBLIs) to carbapenems in two cohorts (empirical therapy cohort, 174 patients, and definitive
therapy cohort, 251 patients) of haematological neutropenic patients with ESBL-producing
Enterobacteriaceae BSI, and did not find any significant difference in 30-day case fatality rates
Table 4. Cox regression analysis for mortality in patients with hematological malignancies and BSI caused by
Escherichia coli.
Variables HR (95% IC) P values
Acute hepatic failure 9.90 (3.08–31.73) <0.001
Septic shock 8.56 (3.33–21.95) <0.001
Male sex 6.46 (2.19–19.01) 0.001
Refractory/Relapsed HM 3.25 (1.35–7.83) 0.008
3rd generation cephalosporins resistance by EC isolate 3.18 (1.36–7.43) 0.007
https://doi.org/10.1371/journal.pone.0224465.t004
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[28]. Probably the role of BLBLIs, and in particular of piperacillin-tazobactam, in treatment
3GCR EC infections should be further investigated, at least in settings as those of HM.
This study has some limitations. As it was carried out in a country with a high prevalence of
3GCR EC, the results may not be generalized, in particular for countries with a different epide-
miological context. In addition, the mechanisms underlying resistance to 3GC in EC isolates
have not been investigated.
In conclusion, in this large multicenter Italian prospective study, we found that, although
the rate of 3GCR EC remained stable trough the recent years, resistance to 3GC adversely
affected the outcomes of EC BSI in HM patients. We also found a significant correlation
between FQ prophylaxis and resistance to 3GC by EC isolates, whereas piperacillin/tazobac-
tam as empirical therapy in the overall cohort of EC BSI patients and as etiological therapy
among 3GCR EC BSI patients was not associated with a worse outcome compared to carbape-
nem-based antimicrobial regimens. Further studies are necessary to investigate the actual role
of FQ prophylaxis in HM patients, especially in settings with high level of antibiotic resistance,
and possible role of piperacillin/tazobactam in treatment of EC BSIs in HM patients.
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